Canada's controlled substances regulations were written for a different era of pharmacy practice. Many of the rules governing how pharmacies handle narcotics, controlled drugs, and targeted substances have not kept pace with how modern pharmacies operate. Health Canada is working to change that.
The Regulatory Modernization Initiative
Health Canada pre-published proposed regulations in June 2024, outlining significant changes to the Controlled Drugs and Substances Act regulations. The final publication is planned for fall 2025, after a period of public consultation and stakeholder feedback. The scope of the changes is broad, touching dispensing, record-keeping, reporting, and operational requirements for pharmacies across the country.
The overarching goal is harmonization. Currently, different classes of controlled substances fall under separate regulatory frameworks: the Narcotic Control Regulations, the Benzodiazepines and Other Targeted Substances Regulations, and parts of the Food and Drug Regulations. Each framework carries its own requirements for record-keeping, security, reporting, and destruction. Pharmacies must navigate overlapping and sometimes contradictory rules depending on the substance being dispensed.
Central Fill for Controlled Substances
One of the most significant proposed changes is enabling central fill for controlled substances. Central fill allows one pharmacy to prepare prescriptions on behalf of another pharmacy, which then dispenses the medication to the patient. This model is already common for non-controlled medications and is widely used by pharmacy chains and mail-order operations.
For controlled substances, central fill has been restricted due to the heightened security and documentation requirements. The proposed regulations would create a framework allowing licensed pharmacies to serve as central fill sites for controlled drugs, subject to specific conditions. Health Canada estimates that approximately 50 pharmacists would initially provide central fill services for controlled substances.
This change has practical implications for efficiency, particularly in rural areas where small pharmacies may not stock the full range of controlled medications. Central fill could improve access while maintaining the regulatory oversight that controlled substances require.
Alignment with Cannabis Regulations
The proposed changes also aim to align controlled substance regulations with the Cannabis Regulations introduced under the Cannabis Act. Since cannabis legalization in 2018, a parallel regulatory framework has developed for cannabis products. The modernization effort seeks to reduce inconsistencies between how cannabis and other controlled substances are regulated at the pharmacy level.
This alignment covers areas such as security requirements for storage, record-keeping standards, and reporting obligations to Health Canada. A more consistent regulatory approach simplifies compliance for pharmacies that handle both cannabis and traditional controlled substances.
Ephedrine and Pseudoephedrine Restrictions
Separate from the broader modernization effort, a Ministerial Order on ephedrine and pseudoephedrine restrictions came into force on May 18, 2025. These precursor chemicals, found in common cold and allergy medications, can be diverted for illicit methamphetamine production.
The new restrictions impose tighter controls on the sale and distribution of products containing ephedrine and pseudoephedrine, including quantity limits, record-keeping requirements, and reporting obligations for pharmacies. These measures bring Canada closer to the regulatory approach used in several other countries that have implemented behind-the-counter or prescription-only status for pseudoephedrine products.
Impact on Pharmacy Operations
Pharmacies across Canada will need to update their standard operating procedures, staff training programs, and technology systems to comply with the new regulations once finalized. Key areas of operational change include updated record-keeping systems that accommodate the harmonized framework, revised security protocols for controlled substance storage, new reporting templates for Health Canada submissions, and central fill agreements and workflows for pharmacies participating in the program.
Pharmacy management software vendors are already preparing updates to accommodate the expected regulatory changes. The transition period following final publication will be critical for ensuring smooth implementation.
What Pharmacists Should Do Now
While the regulations are not yet final, pharmacists and pharmacy managers should begin reviewing the proposed changes published in the Canada Gazette. Understanding the direction of the regulations allows for proactive planning rather than reactive scrambling after the final rules are published.
Provincial pharmacy regulatory authorities will likely issue guidance to help pharmacies interpret and implement the federal changes within their provincial frameworks. Staying connected to both federal and provincial regulatory updates is essential.
PlusVirtual's Commitment to Compliance
At PlusVirtual, regulatory compliance is not an afterthought. We design our systems and processes to meet the highest standards of controlled substance management. As Health Canada modernizes the rules, we are prepared to adapt and ensure our patients continue to receive safe, compliant pharmacy care.